[HTML][HTML] Clinical and molecular analysis of patients with defects in μ heavy chain gene

EL Granados, AS Porpiglia, MB Hogan… - The Journal of …, 2002 - Am Soc Clin Investig
EL Granados, AS Porpiglia, MB Hogan, N Matamoros, S Krasovec, C Pignata, CIE Smith
The Journal of clinical investigation, 2002Am Soc Clin Investig
Autosomal recessive disorders of B cell development are rare and heterogeneous. To
determine the proportion of affected patients who have defects in the μ heavy chain (IGHM)
gene, we used single-stranded conformational polymorphism analysis to screen genomic
DNA from 40 unrelated patients with early onset infections, profound
hypogammaglobulinemia, and absent B cells. All of the patients were genotypically normal
in BTK, the gene that underlies X-linked agammaglobulinemia. Eight different mutations in …
Autosomal recessive disorders of B cell development are rare and heterogeneous. To determine the proportion of affected patients who have defects in the μ heavy chain (IGHM) gene, we used single-stranded conformational polymorphism analysis to screen genomic DNA from 40 unrelated patients with early onset infections, profound hypogammaglobulinemia, and absent B cells. All of the patients were genotypically normal in BTK, the gene that underlies X-linked agammaglobulinemia. Eight different mutations in the μ heavy chain were identified in 19 members of 12 unrelated families. Four of the mutations were large deletions that removed more than 40 kb of DNA in the IGHM locus. In six of the 12 families, the affected patients had an identical single base pair substitution, a G→A, at the –1 position of the alternative splice site. Immunoglobulin haplotype analysis showed that this mutation occurred on at least three different haplotypes, indicating that this is a hot spot for mutations. Compared with patients with mutations in Btk, patients with defects in the μ heavy chain had an earlier onset of disease and more complications. Our study indicates that at least 20–30% of patients with autosomal recessive defects in B cell development have mutations in the μ heavy chain.
The Journal of Clinical Investigation